A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.
Public ClinicalTrials.gov record NCT03770403. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Long-Term, Single-Arm, Open-Label, Multicenter Phase 3 follow-on trial of the ARGX-113-1704 study to evaluate the safety and tolerability of ARGX-113 in patients with gMG. Patients who have completed at least 1 cycle of treatment and at least 1 year of trial ARGX-113-1705 and have started Part B are eligible to enroll in the open-label trial ARGX-113-2002 to receive efgartigimod by SC administration.
Study identification
- NCT ID
- NCT03770403
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 151 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 1, 2019 (Actual)
- Primary completion
- Jun 23, 2022 (Actual)
- Completion
- Jun 30, 2022 (Actual)
- Last update posted
- Jul 14, 2023
2019 – 2022
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator Site 42 | Carlsbad | California | 92011 | — |
| Investigator Site 8 | Los Angeles | California | 90033 | — |
| Investigator Site 33 | Orange | California | 92868 | — |
| Investigator Site 21 | Palo Alto | California | 94304 | — |
| Investigator Site 41 | Jacksonville | Florida | 32209 | — |
| Investigator Site 4 | Tampa | Florida | 33612 | — |
| Investigator Site 14 | Kansas City | Kansas | 66160 | — |
| Investigator Site 32 | Detroit | Michigan | 48201 | — |
| Investigator Site 2 | Chapel Hill | North Carolina | 27599 | — |
| Investigator Site 18 | Cleveland | Ohio | 44195 | — |
| Investigator Site 12 | Portland | Oregon | 97239 | — |
| Investigator Site 1 | Cordova | Tennessee | 38018 | — |
| Investigator Site 3 | San Antonio | Texas | 78229 | — |
| Investigator Site 37 | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03770403, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 14, 2023 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03770403 live on ClinicalTrials.gov.